
PTC Therapeutics, Inc.: updates and filings
Price
$60.23
November 18, 2026Market cap $5.0B
What Ploutos Investor adds for PTC Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 3, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operations, Regulation FD disclosureForm8-K
- Sep 21, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 28, 2026Material agreement enteredForm8-K
- Aug 25, 2026Filing (amendment)Form144/A
- Aug 13, 2026Regulation FD disclosure, other material eventsForm8-K
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operations, officer or director change, Regulation FD disclosureForm8-K
- Jun 18, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, other material eventsForm8-K
- Jun 16, 2026Other material eventsForm8-K
- Jun 9, 2026Officer or director changeForm8-K
- Jun 5, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 28, 2026Regulation FD disclosureForm8-K
- Apr 20, 2026Annual report to shareholdersfor the period to Jan 31, 2026FormARS
- Apr 20, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 3, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Sep 21, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 28, 2026 | 8-K | Material agreement entered | Document |
| Aug 25, 2026 | 144/A | Filing (amendment) | Document |
| Aug 13, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations, officer or director change, Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, other material events | Document |
| Jun 16, 2026 | 8-K | Other material events | Document |
| Jun 9, 2026 | 8-K | Officer or director change | Document |
| Jun 5, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 28, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 20, 2026 | ARS | Annual report to shareholdersfor the period to Jan 31, 2026 | Document |
| Apr 20, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 2, 2004.
The full analysis
What do PTC Therapeutics's filings show?
The filings are where every one of PTC Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.